Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
NCT01047007 · Merck Sharp & Dohme LLC · PHASE1 · terminated · last registry update 2023-09-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study has been terminated due to business reasons.” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against WEE1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-20Also stopped (terminated): National Cancer Institute (NCI), Adavosertib + Cisplatin (NCT03345784)
- 2024-01-10Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Carboplatin + Paclitaxel (NCT02513563)
- 2024-01-03Results posted on the registry: National Cancer Institute (NCI), Adavosertib (NCT01922076)
- 2023-09-18Also stopped (terminated): Merck Sharp & Dohme LLC, adavosertib + Topotecan (NCT01076400)
- 2023-09-13Results posted on the registry: National Cancer Institute (NCI), Adavosertib (NCT03253679)
- 2023-09-08Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Gemcitabine Hydrochloride (NCT02101775)
- 2023-08-14Results posted on the registry: AstraZeneca, Adavosertib (NCT04590248)
- 2023-06-06Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Cisplatin (NCT03345784)
- 2023-04-25Results posted on the registry: National Cancer Institute (NCI), AZD1775 + Gemcitabine (NCT02194829)
- 2022-12-28Results posted on the registry: Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
- 2022-12-28Also stopped (terminated): Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
- 2022-10-05Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Irinotecan Hydrochloride (NCT02095132)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision